The online version of this article (https://doi.org/10.1007/s11060-020-03417-8) contains supplementary material, which is available to authorized users.
M. Gemma Cherry and Michael D. Jenkinson are joint last author.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We conducted a feasibility study to investigate the use of ketogenic diets (KDs) as an adjuvant therapy for patients with glioblastoma (GBM), investigating (i) trial feasibility; (ii) potential impacts of the trial on patients’ quality of life and health; (iii) patients’ perspectives of their decision-making when invited to participate in the trial and (iv) recommending improvements to optimize future phase III trials.
A single-center, prospective, randomized, pilot study (KEATING), with an embedded qualitative design. Twelve newly diagnosed patients with GBM were randomized 1:1 to modified ketogenic diet (MKD) or medium chain triglyceride ketogenic diet (MCTKD). Primary outcome was retention at three months. Semi-structured interviews were conducted with a purposive sample of patients and caregivers (n = 15). Descriptive statistics were used for quantitative outcomes and qualitative data were analyzed thematically aided by NVivo.
KEATING achieved recruitment targets, but the recruitment rate was low (28.6%). Retention was poor; only four of 12 patients completed the three-month diet (MCTKD n = 3; MKD n = 1). Participants’ decisions were intuitive and emotional; caregivers supported diet implementation and influenced the patients’ decision to participate. Those who declined made a deliberative and considered decision factoring diet burden and quality of life. A three-month diet was undesirable to patients who declined and withdrew.
Recruitment to a KD trial for patients with GBM is possible. A six-week intervention period is proposed for a phase III trial. The role of caregivers should not be underestimated. Future trials should optimize and adequately support the decision-making of patients.
Radhakrishnan K, Mokri B, Parisi JE, O’Fallon WM, Sunku J, Kurland LT (1995) The trends in incidence of primary brain tumors in the population of rochester, minnesota. Ann Neurol 37(1):67–73 CrossRef
Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–403 CrossRef
Krex D, Klink B, Hartmann C, Von Deimling A, Pietsch T, Simon M et al (2007) Long-term survival with glioblastoma multiforme. Brain 130(10):2596–2606 CrossRef
Macdonald L (2015) Top 10 priorities for clinical research in primary brain and spinal cord tumours: Final report of the James Lind Alliance Priority Setting Partnership in Neuro-Oncology. www.neuro-oncology.org
Seyfried TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P (2011) Metabolic management of brain cancer. Biochim Biophys Acta 1807(6):577–594 CrossRef
Zhou W, Mukherjee P, Kiebish M, Markis W, Mantis J, Seyfried T (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab 4:5 CrossRef
Tisdale MJ, Brennan RA (1983) Loss of acetoacetate coenzyme A transferase activity in tumours of peripheral tissues. Br J Cancer 47(2):293–297 CrossRef
Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA et al (2014) Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biol 2:1 CrossRef
Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R et al (2008) Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 8:122 CrossRef
Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B (2015) Growth of human colon cancer cells in nude mice is delayed by ketogenic diet with or without omega-3 fatty acids and medium-chain triglycerides. Asian Pacific J Cancer Prev 16(5):2061–2068 CrossRef
Martuscello RT, Vedam-Mai V, Mccarthy DJ, Schmoll ME, Jundi MA, Louviere CD et al (2015) Cancer Therapy: Preclinical A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma. Clin Cancer Res 22(10):2482–2495 CrossRef
Aminzadeh-Gohari S, Feichtinger RG, Vidali S, Locker F, Rutherford T, O’Donnel M et al (2017) A ketogenic diet supplemented with medium-chain triglycerides enhances the anti-tumor and anti-angiogenic efficacy of chemotherapy on neuroblastoma xenografts in a CD1-nu mouse model. Oncotarget 8(39):64728–64744 CrossRef
Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P et al (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE 7(5):e36197. https://doi.org/10.1371/journal.pone.0036197 CrossRefPubMedPubMedCentral
Martin-McGill KJ, Srikandarajah N, Marson AG, Tudur Smith C, Jenkinson MD (2018) The role of ketogenic diets in the therapeutic management of adult and paediatric gliomas: a systematic review. CNS Oncol 7(2):CNS17. CrossRef
Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K et al (2015) Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab 3(3):1–10
Nebeling LC, Miraldi F, Shurin S, Lerner E (1995) Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 14(2):202–208 CrossRef
Moore C, Carter RE, Neitert PJ, Stewart PW (2012) Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci. 4(5):332–337 CrossRef
Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL et al (2016) Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE 11(13):1–22
National Institute for Health Research. Feasibility and Pilot studies. 2019. https://www.nihr.ac.uk/funding-and-support/documents/funding-for-research-studies/research-programmes/PGfAR/FeasibilityandPilot studies.pdf. Accessed on 06 Mar 2019
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820 CrossRef
Jenkinson M. Walton Centre / Clatterbridge Centre for Oncology guidelines for high grade glioma management. Merseyside and Cheshire Neuro-Oncology Clinical Network Group. Liverpool, UK; 2011. https://www.nwcscnsenate.nhs.uk/files/7114/1232/7814/High_grade_glioma_guidelines_November_2013.pdf
Avery KNL, Williamson PR, Gamble C, O’Connell Francischetto E, Metcalfe C, Davidson P et al (2017) Informing efficient randomised controlled trials: exploration of challenges in developing progression criteria for internal pilot studies. BMJ Open 7(2):e013537 CrossRef
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972 CrossRef
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L et al (2010) CONSORT statement: extension to randomised pilot and feasibility trials. BMJ 2016:355
Martin-McGill KJ, Marson AG, Tudur Smith C, Jenkinson MD (2018) The modified ketogenic diet in adults with glioblastoma: an evaluation of feasibility and deliverability within the national health service. Nutr Cancer 70(4):643–649 CrossRef
Walters SJ, Bonacho I, Henriques-Cadby A, Bortolami O, Flight L, Hind D et al (2017) Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open 7:e015276 CrossRef
Bryman A (2016) Mixed methods research: combining quanitative and qualitative research. In: Social research methods. 5th ed. Oxford University Press, Oxford, pp 635–687
Emmel N (2013) Sampling and choosing cases in qualitative research : a realist approach, 1st edn. Mental Health Foundation, London, pp 33–44 CrossRef
Sim J, Saunders B, Waterfield J, Kingstone T (2018) Can sample size in qualitative research be determined a priori? Int J Soc Res Methodol 21(5):619–634. https://doi.org/10.1080/13645579.2018.1454643 CrossRef
Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77–101 CrossRef
O’Cathain A (2018) A practical guide to using qualitative research with randomized controlled trials, 1st edn. Oxford University Press, Oxford CrossRef
Bates AJ, Couillard SA, Arons DF, Yung WKA, Vogelbaum M, Wen PY et al (2017) Hout 15. Brain tumor patient and caregiver survey on clinical trials: identifying attitudes and barriers to patient participation. Neuro Oncol 19(suppl_6):vi109–vi109 CrossRef
Lee EQ, Chukwueke UN, Hervey-Jumper SL, de Groot JF, Leone JP, Armstrong TS et al (2019) Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol 21(9):1100–1117. https://doi.org/10.1093/neuonc/noz104/5513026 CrossRef
Health Research Authority. Good Clinical Practice. 2018. https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/good-clinical-practice/. Accessed 05 Aug 2019
Taylor MK, Sullivan DK, Mahnken JD, Burns JM, Swerdlow RH (2018) Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv 4:28–36. https://doi.org/10.1016/j.trci.2017.11.002 CrossRef
- Ketogenic diets as an adjuvant therapy for glioblastoma (KEATING): a randomized, mixed methods, feasibility study
Kirsty J. Martin-McGill
Anthony G. Marson
Catrin Tudur Smith
Samantha J. Mills
M. Gemma Cherry
Michael D. Jenkinson
- Springer US
Journal of Neuro-Oncology
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
Neu im Fachgebiet Onkologie
Mail Icon II